NCT02824315View on ClinicalTrials.gov

Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Healthy

Interventions

DRUG

AL-335

AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.

DRUG

Odalasvir (ODV)

ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.

DRUG

Simeprevir (SMV)

Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.

Trial Locations (1)

Unknown

Surrey

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02824315 - Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter